AAPL   240.77 (+0.11%)
FB   183.11 (-3.50%)
MSFT   136.82 (-1.17%)
AMZN   1,766.04 (-1.10%)
NVDA   196.74 (+0.37%)
MU   44.78 (-0.97%)
BABA   169.66 (-2.22%)
GE   8.96 (+1.93%)
TSLA   256.64 (+1.23%)
AMD   31.59 (-1.40%)
T   38.27 (+0.10%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.70 (+0.01%)
NFLX   267.50 (-3.79%)
BAC   31.18 (+0.52%)
GILD   66.06 (+1.30%)
DIS   132.95 (+2.07%)
AAPL   240.77 (+0.11%)
FB   183.11 (-3.50%)
MSFT   136.82 (-1.17%)
AMZN   1,766.04 (-1.10%)
NVDA   196.74 (+0.37%)
MU   44.78 (-0.97%)
BABA   169.66 (-2.22%)
GE   8.96 (+1.93%)
TSLA   256.64 (+1.23%)
AMD   31.59 (-1.40%)
T   38.27 (+0.10%)
F   9.07 (+0.44%)
ACB   3.59 (-2.71%)
PRI   125.70 (+0.01%)
NFLX   267.50 (-3.79%)
BAC   31.18 (+0.52%)
GILD   66.06 (+1.30%)
DIS   132.95 (+2.07%)
Log in

Kalvista Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KALV)

$10.98
-0.46 (-4.02 %)
(As of 10/22/2019 03:25 PM ET)
Today's Range
$10.98
Now: $10.98
$11.45
50-Day Range
$10.35
MA: $12.94
$16.42
52-Week Range
$9.86
Now: $10.98
$34.92
Volume4,223 shs
Average Volume198,957 shs
Market Capitalization$195.66 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.13 million
Book Value$5.61 per share

Profitability

Net Income$-20,820,000.00
Net Margins-144.64%

Miscellaneous

Employees33
Market Cap$195.66 million
Next Earnings Date12/13/2019 (Estimated)
OptionableNot Optionable

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.


Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its quarterly earnings results on Monday, September, 9th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.20. The specialty pharmaceutical company earned $3.37 million during the quarter, compared to analysts' expectations of $3.24 million. Kalvista Pharmaceuticals had a negative return on equity of 22.29% and a negative net margin of 144.64%. View Kalvista Pharmaceuticals' Earnings History.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, December 13th 2019. View Earnings Estimates for Kalvista Pharmaceuticals.

What price target have analysts set for KALV?

6 brokers have issued twelve-month price objectives for Kalvista Pharmaceuticals' stock. Their predictions range from $30.00 to $35.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $31.50 in the next year. This suggests a possible upside of 186.9% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

Media headlines about KALV stock have been trending extremely negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Kalvista Pharmaceuticals.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the folowing people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $10.98.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $195.66 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]


MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  382
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel